| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 9 | 2025 | 193 | 3.240 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2025 | 87 | 1.730 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2021 | 74 | 1.490 |
Why?
|
| Mutation | 6 | 2025 | 2612 | 1.310 |
Why?
|
| Immunization, Passive | 9 | 2024 | 105 | 1.000 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2025 | 309 | 0.950 |
Why?
|
| Antibodies, Bispecific | 2 | 2023 | 31 | 0.880 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.850 |
Why?
|
| Neoplastic Stem Cells | 4 | 2013 | 203 | 0.850 |
Why?
|
| Urticaria | 1 | 2023 | 7 | 0.830 |
Why?
|
| Transfusion Reaction | 1 | 2023 | 46 | 0.810 |
Why?
|
| Medicine | 1 | 2023 | 57 | 0.800 |
Why?
|
| Urology | 1 | 2023 | 45 | 0.800 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 23 | 0.700 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 52 | 0.680 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 79 | 0.670 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 352 | 0.600 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 448 | 0.590 |
Why?
|
| Vaccination | 1 | 2021 | 362 | 0.580 |
Why?
|
| Humans | 47 | 2025 | 63449 | 0.560 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1186 | 0.550 |
Why?
|
| Leukemia | 2 | 2016 | 62 | 0.500 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2016 | 11 | 0.490 |
Why?
|
| Antigens, CD34 | 3 | 2017 | 56 | 0.490 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 663 | 0.450 |
Why?
|
| Phenotype | 2 | 2016 | 1207 | 0.450 |
Why?
|
| Neoplasms | 3 | 2023 | 1364 | 0.440 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 67 | 0.430 |
Why?
|
| Stem Cells | 2 | 2013 | 259 | 0.430 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2013 | 284 | 0.420 |
Why?
|
| Prognosis | 5 | 2025 | 1749 | 0.380 |
Why?
|
| Transplantation Conditioning | 2 | 2024 | 102 | 0.360 |
Why?
|
| Male | 19 | 2025 | 29893 | 0.360 |
Why?
|
| Adult | 15 | 2025 | 16826 | 0.360 |
Why?
|
| Aged | 13 | 2025 | 14449 | 0.350 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 412 | 0.350 |
Why?
|
| Disease Progression | 4 | 2024 | 1173 | 0.340 |
Why?
|
| Biomarkers | 1 | 2016 | 1408 | 0.330 |
Why?
|
| Outpatients | 4 | 2024 | 142 | 0.330 |
Why?
|
| Middle Aged | 13 | 2025 | 17615 | 0.330 |
Why?
|
| Female | 20 | 2025 | 32883 | 0.310 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2020 | 20 | 0.300 |
Why?
|
| Cytarabine | 2 | 2020 | 36 | 0.290 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 5463 | 0.280 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 313 | 0.250 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 327 | 0.230 |
Why?
|
| Immunohistochemistry | 2 | 2025 | 896 | 0.220 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.220 |
Why?
|
| Staurosporine | 1 | 2024 | 20 | 0.210 |
Why?
|
| Academies and Institutes | 1 | 2023 | 25 | 0.210 |
Why?
|
| Alleles | 1 | 2025 | 448 | 0.210 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 83 | 0.210 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 172 | 0.210 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 113 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 396 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 188 | 0.190 |
Why?
|
| Adolescent | 5 | 2024 | 6245 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 325 | 0.190 |
Why?
|
| Repressor Proteins | 1 | 2024 | 346 | 0.180 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 507 | 0.180 |
Why?
|
| Blast Crisis | 1 | 2021 | 10 | 0.180 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2012 | 28 | 0.180 |
Why?
|
| Genes, p53 | 1 | 2021 | 52 | 0.180 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2021 | 15 | 0.170 |
Why?
|
| Mullerian Ducts | 1 | 2020 | 6 | 0.170 |
Why?
|
| Congenital Abnormalities | 1 | 2020 | 26 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 98 | 0.170 |
Why?
|
| Ureter | 1 | 2021 | 37 | 0.170 |
Why?
|
| Urinary Retention | 1 | 2021 | 31 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 189 | 0.170 |
Why?
|
| Tretinoin | 3 | 2017 | 50 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 978 | 0.160 |
Why?
|
| Mice, SCID | 2 | 2012 | 519 | 0.160 |
Why?
|
| Anthracyclines | 1 | 2020 | 12 | 0.160 |
Why?
|
| Allografts | 1 | 2020 | 46 | 0.160 |
Why?
|
| Mice, Inbred NOD | 2 | 2012 | 525 | 0.160 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2019 | 8 | 0.160 |
Why?
|
| Voriconazole | 1 | 2019 | 6 | 0.160 |
Why?
|
| Invasive Fungal Infections | 1 | 2019 | 7 | 0.160 |
Why?
|
| Robotics | 1 | 2021 | 87 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 89 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 772 | 0.150 |
Why?
|
| Hospitalization | 2 | 2024 | 1364 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 12 | 0.150 |
Why?
|
| Antifungal Agents | 1 | 2019 | 129 | 0.150 |
Why?
|
| Immunophenotyping | 2 | 2016 | 196 | 0.150 |
Why?
|
| Bone Marrow | 3 | 2016 | 180 | 0.150 |
Why?
|
| Tacrolimus | 1 | 2018 | 65 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 536 | 0.140 |
Why?
|
| Child | 3 | 2023 | 4526 | 0.140 |
Why?
|
| Telemedicine | 1 | 2023 | 326 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 238 | 0.140 |
Why?
|
| Kidney | 1 | 2020 | 446 | 0.140 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 49 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2023 | 712 | 0.140 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 191 | 0.140 |
Why?
|
| United States | 5 | 2023 | 7843 | 0.140 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 161 | 0.140 |
Why?
|
| Myelopoiesis | 1 | 2017 | 14 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2024 | 739 | 0.130 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.130 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2016 | 4 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 378 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2017 | 3035 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 45 | 0.130 |
Why?
|
| Arabinonucleosides | 1 | 2016 | 2 | 0.130 |
Why?
|
| Adenine Nucleotides | 1 | 2016 | 4 | 0.130 |
Why?
|
| Mastocytosis | 1 | 2016 | 2 | 0.120 |
Why?
|
| Etoposide | 1 | 2016 | 34 | 0.120 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2016 | 10 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2021 | 492 | 0.120 |
Why?
|
| Karyotyping | 1 | 2016 | 48 | 0.120 |
Why?
|
| Dermatomycoses | 1 | 2016 | 14 | 0.120 |
Why?
|
| Leukopenia | 1 | 2016 | 16 | 0.120 |
Why?
|
| Niacinamide | 1 | 2016 | 33 | 0.120 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 32 | 0.120 |
Why?
|
| Cell Differentiation | 4 | 2017 | 1353 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2013 | 226 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2017 | 187 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2016 | 186 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 168 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 348 | 0.120 |
Why?
|
| Young Adult | 4 | 2025 | 4695 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 238 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1553 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2013 | 988 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2013 | 319 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5680 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 422 | 0.110 |
Why?
|
| Neutrophils | 1 | 2017 | 377 | 0.110 |
Why?
|
| Automation, Laboratory | 1 | 2013 | 8 | 0.110 |
Why?
|
| Tissue Donors | 2 | 2024 | 153 | 0.100 |
Why?
|
| Mice | 6 | 2013 | 10845 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 16 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 37 | 0.100 |
Why?
|
| Splenic Rupture | 1 | 2013 | 2 | 0.100 |
Why?
|
| Sarcoma, Myeloid | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cyclin D1 | 1 | 2013 | 17 | 0.100 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2013 | 15 | 0.100 |
Why?
|
| Recurrence | 2 | 2012 | 641 | 0.100 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 58 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 71 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 457 | 0.100 |
Why?
|
| Transplantation, Autologous | 2 | 2024 | 127 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 172 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2013 | 374 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 139 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 44 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2157 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 147 | 0.090 |
Why?
|
| Cytosine | 1 | 2011 | 31 | 0.090 |
Why?
|
| DNA Repair | 1 | 2013 | 248 | 0.090 |
Why?
|
| WT1 Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 46 | 0.090 |
Why?
|
| Myeloblastin | 1 | 2011 | 15 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 13 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 39 | 0.090 |
Why?
|
| Telomerase | 1 | 2011 | 31 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 167 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 115 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 136 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2023 | 3293 | 0.080 |
Why?
|
| Transcriptome | 1 | 2013 | 387 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 770 | 0.080 |
Why?
|
| Cytokines | 2 | 2023 | 935 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6659 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 222 | 0.080 |
Why?
|
| Animals | 6 | 2013 | 20663 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 55 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 864 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 348 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 1277 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 672 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 418 | 0.070 |
Why?
|
| Cell Movement | 1 | 2009 | 454 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 572 | 0.060 |
Why?
|
| Transplantation, Haploidentical | 1 | 2024 | 4 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1537 | 0.060 |
Why?
|
| HLA Antigens | 1 | 2024 | 63 | 0.050 |
Why?
|
| Blood Donors | 1 | 2024 | 23 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 245 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2024 | 26 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2023 | 30 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2023 | 88 | 0.050 |
Why?
|
| Safety-net Providers | 1 | 2023 | 30 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2023 | 7 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 180 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 183 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1198 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 209 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 321 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 459 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 213 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 113 | 0.040 |
Why?
|
| Replantation | 1 | 2021 | 12 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2021 | 45 | 0.040 |
Why?
|
| Sweden | 1 | 2020 | 58 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 136 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2022 | 311 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 158 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 54 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2020 | 267 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 65 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 864 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 663 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2017 | 25 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2017 | 29 | 0.030 |
Why?
|
| Neutrophil Activation | 1 | 2017 | 24 | 0.030 |
Why?
|
| Lactoferrin | 1 | 2017 | 37 | 0.030 |
Why?
|
| Isoleucine | 1 | 2016 | 9 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 60 | 0.030 |
Why?
|
| Exocytosis | 1 | 2017 | 60 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1147 | 0.030 |
Why?
|
| Threonine | 1 | 2016 | 16 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 61 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 138 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 231 | 0.030 |
Why?
|
| Arsenicals | 1 | 2016 | 8 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 6 | 0.030 |
Why?
|
| Oxides | 1 | 2016 | 37 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2335 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 240 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 1644 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1990 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 664 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2013 | 4 | 0.030 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 1 | 2013 | 4 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 27 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 29 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 92 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 11 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 21 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 65 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 109 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2013 | 55 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2013 | 140 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 41 | 0.030 |
Why?
|
| DNA Primers | 1 | 2013 | 293 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 207 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 1603 | 0.020 |
Why?
|
| Spleen | 1 | 2013 | 483 | 0.020 |
Why?
|
| 5-Methylcytosine | 1 | 2011 | 21 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 443 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 189 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 157 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 198 | 0.020 |
Why?
|
| Software | 1 | 2013 | 389 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 629 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 622 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1654 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2009 | 77 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 1470 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3396 | 0.010 |
Why?
|